Our current working hypothesis is that peripheral administration of CXCL10-Ig or CXCL9-Ig would induce the activity of CXCR3+ effector CD4+ T cells, effector CD8+ T cells, and NK cells that are then recruited to at the tumor sites to limit cancer. This evidence concerns the gene CD8A and cancer.